Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results propelled the company’s stock (NASDAQ:SNGX) a hefty 134% higher on July 31, with shares closing at $2.93 each.
A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc. presented clinical data at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, showing comparable efficacy and safety to the FDA-approved intravenous formulation.
Around 10 million people globally live with the life-threatening human T-cell lymphotropic virus type-1 (HTLV-1), yet it remains a poorly understood disease that currently has no preventative treatments and no cure. That could soon change after Australian researchers discovered that existing HIV drugs can suppress transmission of the HTLV-1 virus in mice.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alpha Cognition, Apellis, Calidi, Eisai, Intrabio, Johnson&Johnson, Lithea, Metriopharm, Nektar, PTC, Sarepta.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bausch, BMS, Cingulate, Durect, Eli Lilly, Exelixis, Formation Bio, Imidomics, LTZ, Neurox, Quion, Relief.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acumen, Aim, Alfasigma, Alterity, Alzcure, Celcuity, Cervomed, Cognition, Eli Lilly, Fulcrum. Nkgen, Recognify, Servier, Taran, Urogen.
As biotech zombies with failed programs and money in hand go, Galapagos NV is a notable example, with a number of misses in the clinic, $3.1 billion in the bank, and a market capitalization of $2.19 billion.
RSS
